Acurx Pharmaceuticals, Inc. (ACXP)

The short-term outlook remains deeply bearish due to a catastrophic multi-year price collapse. Despite a recent 29% surge driven by clinical trial optimism, the stock is trading at a fraction of its historical value, having lost nearly 95% of its worth over the last four years. The technical picture is grim, with the current price significantly below both the 50-day and 200-day moving averages, indicating persistent selling pressure and a lack of established support. While the recent news highlights potential breakthroughs in antibiotic research, the market has already priced in significant recovery, leaving little room for error given the company's history of steep declines. From a long-term perspective, the investment case is severely compromised by deteriorating fundamentals and a broken equity structure. The company is burning through cash with negative free cash flow and negative returns on assets and equity. More critically, the stock has undergone a massive reverse split (evidenced by the drop from ~$92 to ~$4.72 in a single year), which often signals distress and erodes investor confidence. Although the latest year showed a temporary rebound, the overwhelming trend is one of structural failure, with the business failing to generate sustainable value or profitability. The balance sheet, while currently showing a positive book value, is fragile given the ongoing cash burn and the dilution risks associated with such a distressed capital structure. Finally, there is no dividend component to consider. As a biotechnology firm focused on R&D and clinical trials, the company is reinvesting all available capital into operations rather than returning cash to shareholders. There is no history of payouts, making this a pure equity play on a high-risk turnaround story.